Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of fasiglifam added to metformin versus placebo and sitagliptin in type 2 diabetes
2011-001752-10Phase 3Terminated
- Sponsor
- Takeda
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fasiglifam in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Takeda. Primary endpoint: Change from baseline in HbA1c over 24 weeks. Started Jul 2012; status: terminated.
02
Drugs
fasiglifam
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-001752-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001752-10.